ArticleMedComm2025

Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose-Escalation Phase I Trial Study.

Xu Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.